The breadth of independent research supports vonoprazan's scientific credibility, but no immediate catalyst for stock movement. Monitor for potential label expansion or competitive positioning based on future regulatory actions.
Price Chart
Executive Summary
Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study recognized as a Poster of Distinction. The data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic care, but no new regulatory actions or financial guidance were provided.
Key Facts
- 31 vonoprazan-related abstracts presented at DDW 2026, including 28 independent investigator-initiated studies
- Phathom-sponsored analysis from Phase 3 pHalcon-NERD-301 study recognized as Poster of Distinction
- Data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use
- No new FDA decisions, label expansions, or financial updates announced
Financial Impact
No financial impact from this press release; revenue and guidance unchanged.
Risk Factors
- Investor expectations for near-term label expansion may be disappointed if no FDA action follows
- Competitive pressure from PPIs and other PCABs may limit commercial uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298395 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | 8-K | $9.03 $8.94 | ▼ −1.00% | ▼ −4.96% | $6.92 (−23.37%) |
Jul 30, 2026 9w ago | Press Release | $9.03 $8.94 | ▲ +1.00% | ▲ +4.96% | $6.92 (+23.37%) |
Jul 20, 2026 10w ago | Press Release | $10.65 $9.28 | ▲ +12.86% | ▲ +16.98% | $6.92 (+35.02%) |
May 20, 2026 19w ago | Press Release | $11.87 $10.88 | ▼ −8.34% | ▼ −9.08% | $6.92 (−41.70%) |
May 1, 2026 22w ago | Press Release | $12.01 $9.24 | ▼ −23.06% | ▼ −28.35% | $6.92 (−42.38%) |
Apr 30, 2026 22w ago | Press Release | $11.20 $10.32 | ▼ −7.86% | ▼ −12.82% | $6.92 (−38.21%) |
Apr 7, 2026 25w ago | DEFA14A | $11.55 $12.87 | ▲ +11.43% | ▲ +1.65% | $6.92 (−40.09%) |
Feb 26, 2026 31w ago | 8-K | $13.56 $10.79 | ▼ −20.43% | ▼ −14.03% | $6.92 (−48.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access